Veteran healthcare and consumer technology operator turned investor with experience scaling growth-stage companies and advising boards on commercial strategy and go-to-market execution. Jane Bortnem has led marketing and product functions at venture-backed startups and served as an executive-in-residence and angel investor, focusing on customer acquisition, retention economics and category expansion. Market relevance centers on growth equity and early-stage rounds where operational playbooks and customer-driven scaling drive valuation upside.
Veteran healthcare and consumer technology operator turned investor with experience scaling growth-stage companies and advising boards on commercial strategy and go-to-market execution. Jane Bortnem has led marketing and product functions at venture-backed startups and served as an executive-in-residence and angel investor, focusing on customer acquisition, retention economics and category expansion. Market relevance centers on growth equity and early-stage rounds where operational playbooks and customer-driven scaling drive valuation upside.
Focuses on growth-stage healthcare and consumer technology companies where operator-led capital accelerates customer acquisition and retention-driven revenue. Prefers early growth equity and seed rounds, underwriting opportunities through unit-economics, payback period and category expansion potential. Deploys smaller, active checks coupled with board or advisor roles to drive go-to-market execution, product-market fit and scalable acquisition channels. Time horizon is multi-year, value creation through commercial scaling and disciplined follow-on allocation to protect ownership and upside.
Focuses on growth-stage healthcare and consumer technology companies where operator-led capital accelerates customer acquisition and retention-driven revenue. Prefers early growth equity and seed rounds, underwriting opportunities through unit-economics, payback period and category expansion potential. Deploys smaller, active checks coupled with board or advisor roles to drive go-to-market execution, product-market fit and scalable acquisition channels. Time horizon is multi-year, value creation through commercial scaling and disciplined follow-on allocation to protect ownership and upside.
| Trades 3636 | Longs Won 2542/3636 69% | Profit Factor 18.44 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $283,512.57 |
| Average Win $48,228.22 | Best Trade (Oct 16) $7.08M | Sharpe Ratio -8.63 |
| Average Loss -$6,077.54 | Worst Trade (Oct 16) -$1.57M | Z-Score 14.74 (100%) |
| Commissions $0 | Avg. Trade Length 1y 8m 1w 3d | Expectancy $31,888.7 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 90,909 | 81,818 | 72,727 | 63,636 | 54,545 | 45,455 | 36,364 | 27,273 | 18,182 | 9,091 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| 2523 25239Y147 | 3,231 | $78,061 | $78,061 | - | - | - | 0.0 |
| 2523 25239Y170 | 1,962 | $73,517 | $73,517 | - | - | - | 0.0 |
| 2523 25239Y196 | 204,051 | $8.55M | $8.55M | - | - | - | 0.0 |
AAPL Apple Inc. | 12,696 | $2.5M | $4.34M | - | $1.85M | 73.93% | -0.28% |
AAXJ iShares MSCI All Country Asia ex Japan ETF | 1,865 | $123,931.87 | $205,821.4 | - | $81,889.53 | 66.08% | -0.791% |
ABBV AbbVie Inc. | 177 | $30,308.63 | $50,161.8 | - | $19,853.17 | 65.5% | +0.586% |
ABT Abbott Laboratories | 1,416 | $177,411.03 | $148,226.88 | - | -$29,184.15 | -16.45% | +2.286% |
ACN Accenture plc Class A | 253 | $68,725.29 | $56,904.76 | - | -$11,820.53 | -17.2% | +4.633% |
ACWI iShares MSCI ACWI ETF | 68 | $6,524.47 | $10,827.64 | - | $4,303.17 | 65.95% | +0.302% |
ADAM Adamas Trust, Inc. | 6 | $60 | $45 | - | -$15 | -25% | 0.0 |
ADI Analog Devices, Inc. | 27 | $5,259.89 | $10,906.65 | - | $5,646.76 | 107.36% | +0.094% |
ADP Automatic Data Processing Inc. | 454 | $100,900.12 | $129,685.1 | - | $28,784.98 | 28.53% | +1.901% |
AFK VanEck Vectors Africa Index ETF | 462 | $11,259 | $12,081.3 | - | $822.3 | 7.3% | 0.0 |
AFL Aflac Inc. | 76 | $8,451 | $8,971.8 | - | $520.8 | 6.16% | -0.135% |
AGG iShares Core U.S. Aggregate Bond ETF | 21,253 | $2.08M | $2.03M | - | -$56,150.16 | -2.69% | +0.622% |
AGZD WisdomTree Trust | 3,234 | $71,536.08 | $73,217.76 | - | $1,681.68 | 2.35% | +0.3% |
AIG American International Group Inc. | 10 | $547 | $791.2 | - | $244.2 | 44.64% | +2.183% |
AIRR First Trust RBA American Industrial Renaissance ETF | 345 | $21,344.74 | $34,641.45 | - | $13,296.71 | 62.3% | +0.884% |
ALRS Alerus Financial Corporation | 830 | $15,365.04 | $25,489.3 | - | $10,124.26 | 65.89% | +0.098% |
AMAT Applied Materials, Inc. | 265 | $38,930.13 | $113,952.65 | - | $75,022.52 | 192.71% | -3.721% |